jornay vs vyvanse
MSN: Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability Tupper reaffirmed 2026 product revenue guidance of $805 million to $825 million, citing a 4% increase year-over-year, driven by Jornay growth and durable revenues from the pain portfolio. Jornay ... Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability Earnings call Collegium reported 2025 net revenue of $780.6M, up 24% year-over-year, with adjusted EBITDA rising 15% to $460.5M. Jornay PM prescriptions grew 20% and revenue surged 48%. 2026 guidance ... Nasdaq: Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
Nasdaq: Collegium Pharmaceutical to Present Real-World Data on Jornay PM at NAPNAP 46th National Conference Collegium Pharmaceutical, Inc. announced that it will present two posters featuring real-world data on its ADHD treatment, Jornay PM (methylphenidate HCl), at the NAPNAP National Conference in Chicago ...
Vyvanse vs. Adderall for ADHD: What's the Difference?
